Table 1.

Definitions of proposed clinical subgroups of AIH and treatment outcomes

Condition	Definition
Acute severe AIH	Jaundice, PT-INR ≥1.5, no encephalopathy; no previously diagnosed liver disease [1]
ALF-AIH	Jaundice, PT-INR ≥1.5, hepatic encephalopathy within 26 weeks of onset of illness; no previously diagnosed liver disease [1]
Biochemical remission	Normalization of serum AST, ALT, and IgG within ULN [1]
Incomplete response	Improvement of laboratory findings, but not to fulfill criteria for remission
Treatment failure	Worsening laboratory and histological findings under strict adherence to prescribed medication
Treatment intolerance	Inability to adhere to maintenance therapy due to drug-related side effects
Relapse	Exacerbation of disease activity after biochemical remission or nonadherence

AIH, autoimmune hepatitis; PT, prothrombin time; INR, international normalized ratio; ALF, acute liver failure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IgG, immunoglobulin G; ULN, upper limit of normal.